Cannabis for Multiple Sclerosis in Australia — Spasticity, Pain & How to Access (2026)

Multiple sclerosis (MS) affects approximately 33,000 Australians — one of the highest rates per capita in the world. It is a chronic, often progressive autoimmune disease in which the immune system attacks the myelin sheath protecting nerve fibres, disrupting communication between the brain and the body. Symptoms vary widely by individual and disease stage but typically include spasticity and muscle spasms, neuropathic pain, fatigue, bladder dysfunction, cognitive difficulties and sleep disruption.

Medicinal cannabis has become one of the most widely discussed adjunct treatments in MS care. Of all neurological conditions, MS has the strongest and most established evidence base for cannabis — particularly for spasticity — and it is one of the conditions most frequently cited in TGA medicinal cannabis prescriptions across Australia.

This guide covers what the research shows, which symptoms respond best, how to choose products, and how to access cannabis legally in Australia.

How cannabis affects the MS-affected nervous system

The endocannabinoid system (ECS) plays a central role in neuroprotection, immune modulation and the regulation of muscle tone — all of which are directly relevant to MS.

CB1 receptors are densely expressed throughout the central nervous system, including in motor circuits, pain processing pathways and the bladder control centres. CB2 receptors are concentrated in immune cells, including the microglia and T cells implicated in MS lesion formation. This dual distribution means cannabis has several mechanistic pathways relevant to MS:

• Spasticity reduction: THC acts on CB1 receptors in the spinal cord and brainstem to reduce the pathologically elevated muscle tone that causes spasticity and spasms
• Pain modulation: Both THC and CBD reduce neuropathic pain signalling through CB1 agonism and TRPV1 desensitisation
• Neuroinflammation: CB2 agonism modulates microglial activity and cytokine production — reducing the inflammatory signalling that drives MS lesion formation and symptom exacerbation
• Bladder function: The urothelium (bladder lining) expresses CB1 and CB2 receptors; cannabinoids may reduce bladder overactivity and urgency

Clinical evidence: what the research shows

Spasticity — the strongest evidence

MS-related spasticity has the most robust evidence base of any cannabis-treatable symptom. Several landmark trials underpin this:

The CAMS Study (2003): A 657-patient UK randomised controlled trial of oral THC and cannabis extract for MS spasticity found significant improvements in patient-reported spasticity, spasms, pain and sleep quality, despite modest effects on the primary objective spasticity measure (Ashworth scale). The CAMS study was pivotal in establishing that patient-reported spasticity benefit from cannabis is real and clinically meaningful, even when objective measures show limited change.

Sativex (nabiximols): A THC:CBD oromucosal spray, Sativex is the world’s most extensively studied cannabis product for MS. Multiple Phase 3 RCTs demonstrated it significantly reduced patient-reported spasticity scores in people who had failed conventional antispasmodics. Sativex is TGA-registered in Australia for MS spasticity (prescription required) and represents a high-quality, consistent product with a well-characterised evidence base.

Cochrane Review (2018): A systematic review of 17 randomised trials found moderate-quality evidence that cannabis-based medicines (oral THC, nabiximols) improve patient-reported spasticity, sleep and pain in MS. The evidence was insufficient to demonstrate effect on objective spasticity measures but was consistent for subjective patient benefit.

Neuropathic pain

Neuropathic pain — burning, electric or stabbing sensations arising from damaged nerve fibres — affects approximately 50% of people with MS. Cannabis is well-evidenced for neuropathic pain more broadly, and MS neuropathic pain responds similarly. Balanced THC:CBD products are most commonly prescribed; the CBD component reduces the psychoactive load while contributing analgesic effect through different pathways.

Bladder dysfunction

A 2003 randomised controlled trial specifically examining cannabis for MS bladder dysfunction found significant reductions in urge incontinence episodes, frequency and nocturia compared to placebo. The mechanism is via CB1 receptor agonism in the bladder wall reducing detrusor overactivity. This is an area where many MS patients who try cannabis report unexpectedly strong benefit.

Fatigue and cognitive function

MS fatigue — described by patients as a crushing, overwhelming exhaustion distinct from ordinary tiredness — is one of the most disabling MS symptoms. Evidence for cannabis in MS fatigue is weaker and mixed. Some patients report improved energy and reduced fatigue, while others find THC increases sedation. CBD-dominant products may be better tolerated for this indication. Important caveat: High-THC products can impair cognitive function — a real concern in patients who already have MS-related cognitive difficulties.

Sleep

Poor sleep quality, often driven by pain, spasticity and nocturia, affects up to 50% of MS patients. Cannabis consistently improves sleep in MS clinical trials, partly as a secondary benefit of spasticity and pain reduction. Read our dedicated sleep guide.

Sativex vs other cannabis products: which should MS patients use?

	Sativex (nabiximols)	Medicinal cannabis oils/capsules	Vaporised flower
THC:CBD ratio	1:1	Variable	Variable
Evidence base	Strongest (MS-specific RCTs)	Good (general cannabis evidence)	Moderate
Dose consistency	Highly consistent per spray	Consistent per product	Variable
TGA status	Registered	SAS-B	SAS-B
Cost	High	Moderate	Moderate
Onset	15–40 min (oromucosal)	30–90 min (oil)	5–15 min
Best for	Spasticity (first-line cannabis option)	Pain, sleep, general symptom management	Acute spasm breakthrough

Sativex is the most evidence-backed option for MS spasticity specifically and is often the first cannabis product neurologists will consider. However, it is expensive (~$400–600/month) and access requires a prescription from a neurologist or GP familiar with MS management.

Medicinal cannabis oils with a balanced THC:CBD ratio (1:1 or 2:1) offer a more cost-effective alternative, with good evidence for pain and sleep and reasonable evidence for spasticity. These are more flexible in dosing.

Practical guide to using cannabis for MS symptoms

For spasticity and muscle spasms

First choice: Balanced THC:CBD oil (1:1 ratio) or Sativex, taken 2–3 times per day.

Start at 2.5mg THC + 2.5mg CBD per dose. Assess after 7–10 days. Most MS patients find their effective spasticity dose between 5–20mg THC daily (in divided doses). Take consistently throughout the day rather than as-needed — sustained plasma levels are more effective for tonic spasticity than acute dosing.

For acute spasms (breakthrough): Vaporised low-THC flower provides rapid relief (5–15 min) and can manage acute spasm episodes. Limit to 1–2 inhalations of low-to-moderate THC flower (12–18% THC). Browse indica-dominant flower options — the body-relaxing, muscle-calming profile of indica genetics is generally preferred for spasticity.

For neuropathic pain

First choice: Balanced THC:CBD oil or CBD-dominant oil taken morning, midday and evening.

Neuropathic pain often responds better to consistent dosing than to as-needed use. CBD’s TRPV1-mediated pain reduction and THC’s CB1-mediated analgesia work synergistically. Starting dose: 25–50mg CBD + 2.5–5mg THC three times daily.

For bladder symptoms

The clinical evidence for cannabis in MS bladder dysfunction is specifically for THC-containing products, not CBD alone. A low-to-moderate THC dose (5–10mg) taken 2–3 times daily has shown the most consistent effect on bladder urgency and incontinence in trials. Timing around most problematic periods (evening, overnight) can be particularly helpful for nocturia.

For sleep

A CBD-dominant or balanced oil taken 60–90 minutes before sleep addresses both the pain/spasticity-driven sleep disruption and primary insomnia. See our sleep guide for dosing details.

Note on driving: THC-containing products impair driving and cannabis is detectable in oral fluid and blood. If you drive and have MS, discuss timing of THC doses with your prescriber — morning THC use in particular requires careful consideration. CBD-only products do not impair driving.

Cannabis and MS disease-modifying therapy (DMT): interactions

Most people with MS are on disease-modifying therapies. The interaction picture is relatively reassuring but not zero-risk.

CBD inhibits CYP3A4 and CYP2C9 enzymes. Some DMTs — including fingolimod and dimethyl fumarate — are metabolised by these pathways. In practice, significant interactions are not commonly reported in MS patients using typical medicinal cannabis doses, but formal pharmacokinetic studies are limited.

Practical guidance:

• Disclose cannabis use to your neurologist before starting
• If on multiple sclerosis DMTs, start with CBD-dominant products first to assess tolerability before adding THC
• Monitor for unexpected increases in DMT side effects (which might indicate raised drug plasma levels)

Interferon beta products (Avonex, Betaferon) are not significantly metabolised by CYP450 — interaction risk with cannabis is considered low.

How to access medicinal cannabis for MS in Australia

Step 1: Your neurologist Your MS neurologist is the best first contact. Many Australian neurologists now actively prescribe medicinal cannabis, particularly Sativex for spasticity. Ask specifically about medicinal cannabis at your next review — do not wait for it to be raised.

Step 2: GP prescription via SAS-B If your neurologist is not familiar or comfortable with cannabis prescribing, your GP can prescribe under the TGA’s SAS-B framework. Bring documentation of your MS diagnosis, current DMT and a list of spasticity/pain medications already tried.

Step 3: Telehealth platforms Alternaleaf, Polln and Leafio offer telehealth consultations specialising in medicinal cannabis. Initial appointments typically cost $50–150 and can be booked quickly. Bring your MS diagnosis and neurologist’s contact details.

MS Australia provides information resources for people with MS exploring medicinal cannabis — their website is a useful starting point for understanding the current state of evidence: msaustralia.org.au

Cost: Sativex costs approximately $400–600/month. Medicinal cannabis oils and capsules typically cost $100–300/month. Not PBS-listed. Some private health insurers offer partial reimbursement.

What to realistically expect

Cannabis is not a cure for MS and does not modify the underlying disease course in clinical practice. What it can realistically offer:

• Spasticity: Meaningful reduction in muscle stiffness and spasm frequency for most patients who trial it — particularly those who have had inadequate response to baclofen or tizanidine
• Pain: Moderate reduction in neuropathic pain severity; most patients describe it as reducing pain to a more manageable level rather than eliminating it
• Sleep: Consistent improvement, particularly when sleep disruption is driven by pain and spasticity
• Bladder: Modest reduction in urgency and incontinence episodes in patients with neurogenic bladder

Allow 4–8 weeks at a stable dose before assessing overall response. Keep a symptom diary (spasm frequency, pain score, sleep hours, bladder episodes) to track changes objectively.

Frequently asked questions

Is cannabis legal for MS in Australia? Yes, with a prescription. Cannabis for MS is prescribed under the TGA’s Special Access Scheme B (SAS-B) by GPs or specialists. Sativex (nabiximols) is a TGA-registered product specifically for MS spasticity. No government pre-approval is needed — your prescriber handles the process.

Can cannabis help MS spasticity when other medications haven’t worked? Yes — this is a primary indication. Australian neurologists frequently prescribe cannabis for MS spasticity in patients who have had insufficient response to baclofen, tizanidine or diazepam. The evidence specifically for treatment-refractory spasticity is among the strongest in the medicinal cannabis literature.

Will cannabis make MS fatigue better or worse? Variable. Some patients find CBD-dominant products improve energy and reduce fatigue. THC-dominant products can increase sedation and worsen fatigue in some people. Start with CBD-dominant products and add THC cautiously if fatigue is a concern. Avoid high-THC doses during the day.

Does cannabis affect MS cognitive function? THC at high doses can impair short-term memory and processing speed — functions already affected in many MS patients. This makes careful dose management particularly important. CBD-dominant products have minimal cognitive impact. Low-THC balanced products used as directed by a prescriber are generally considered manageable, but patients with significant cognitive MS symptoms should start at the lowest possible THC dose.

Is Sativex (nabiximols) available in Australia? Yes. Sativex is TGA-registered in Australia for MS spasticity and requires a prescription. It is the most evidence-based cannabis product for MS spasticity but is expensive (~$400–600/month) and not PBS-listed. Ask your neurologist or GP about prescribing options.

Can cannabis slow MS progression? There is no clinical evidence that cannabis modifies MS disease course in humans. It manages symptoms — spasticity, pain, bladder dysfunction, sleep — but does not slow lesion accumulation or disability progression. Continue disease-modifying therapy alongside cannabis.

How long does it take for cannabis to help MS symptoms? Acute effects (spasm reduction, pain relief) can be felt within hours of the first THC-containing dose. Consistent, sustained symptom control typically takes 2–4 weeks at stable doses as the medication levels in the body and sleep improves as a secondary benefit. Full assessment of response should be made at 8 weeks.